Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)
- Authors:
- Xiao Wang
- Jingwei Shi
- Zhengcheng Liu
-
Affiliations: Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China, Department of Thoracic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China - Published online on: February 9, 2024 https://doi.org/10.3892/mco.2024.2726
- Article Number: 28
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer: Apr 5, 2021 (Epub ahead of print). | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global CANCER Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Deo SVS, Sharma J and Kumar S: GLOBOCAN 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists. Ann Surg Oncol. 29:6497–6500. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang M, Herbst RS and Boshoff C: Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 27:1345–1356. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Mattiuzzi C and Lippi G: Cancer statistics: A comparison between World Health Organization (WHO) and global burden of disease (GBD). Eur J Public Health. 30:1026–1027. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xi KX, Zhang XW, Yu XY, Wang WD, Xi KX, Chen YQ, Wen YS and Zhang LJ: The role of plasma miRNAs in the diagnosis of pulmonary nodules. J Thorac Dis. 10:4032–4041. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Nooreldeen R and Bach H: Current and future development in lung cancer diagnosis. Int J Mol Sci. 22(8661)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wen M, Wang L, Wang X, Yang S, Sun Y, Xia J, Zhang Y, Zhang Z, Huang L and Jiang T: Optimal adjuvant therapy in resected stage IIIA-N2 non-small-cell lung cancer harboring EGFR mutations. Oncol Res Treat. 43:686–693. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, et al: Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 39:713–722. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Colletti PM: Earlier diagnosis of subcentimeter lung cancers is not self-evidently beneficial: Personal experience. AJR Am J Roentgenol. 213:819–820. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Shin KE, Lee KS, Yi CA, Chung MJ, Shin MH and Choi YH: Subcentimeter lung nodules stable for 2 years at LDCT: Long-term follow-up using volumetry. Respirology. 19:921–928. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Heuvelmans MA, Groen HJ and Oudkerk M: Early lung cancer detection by low-dose CT screening: Therapeutic implications. Expert Rev Respir Med. 11:89–100. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Reich JM and Kim JS: Earlier diagnosis not self-evidently beneficial: Natural history of subcentimeter lung cancers. AJR Am J Roentgenol. 213:817–818. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Parikh AR: Lung cancer genomics. Acta Med Acad. 48:78–83. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Imyanitov EN, Iyevleva AG and Levchenko EV: Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit Rev Oncol Hematol. 157(103194)2021.PubMed/NCBI View Article : Google Scholar | |
|
Rammal S, Kourie HR, Jalkh N, Mehawej C, Chouery E, Moujaess E and Dabar G: Molecular pathogenesis of hereditary lung cancer: A literature review. Pharmacogenomics. 22:791–803. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Hu B, Ren W, Feng Z, Li M, Li X, Han R and Peng Z: Correlation between CT imaging characteristics and pathological diagnosis for subcentimeter pulmonary nodules. Thorac Cancer. 13:1067–1075. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Ruiz-Cordero R and Devine WP: Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 13:17–33. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Miller M and Hanna N: Advances in systemic therapy for non-small cell lung cancer. BMJ. 375(n2363)2021.PubMed/NCBI View Article : Google Scholar | |
|
Schuler M, Bölükbas S, Darwiche K, Theegarten D, Herrmann K and Stuschke M: Personalized treatment for patients with lung cancer. Dtsch Arztebl Int: arztebl.m2023.012, 2023 (Epub ahead of print). | |
|
Wu F, Wang L and Zhou C: Lung cancer in China: Current and prospect. Curr Opin Oncol. 33:40–46. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Sherry V: Lung cancer: Prevention and early identification are key. Nurse Pract. 47:42–47. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Mazzone PJ and Lam L: Evaluating the patient with a pulmonary nodule: A review. JAMA. 327:264–273. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Hansell DM, Bankier AA, Macmahon H, McLoud TC, Müller NL and Remy J: Fleischner Society: glossary of terms for thoracic imaging. Radiology. 246:697–722. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Sun Z, Li Y, Qi Q, Huang H, Wang X, Zhou J, Liu K, Yin P, Wang Z, et al: Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions. Lung Cancer. 166:178–188. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Lv Y and Ye B: Advances in diagnosis and management of subcentimeter pulmonary nodules. Zhongguo Fei Ai Za Zhi. 23:365–370. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, Franks K, Gleeson F, Graham R, Malhotra P, et al: British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 70 (Suppl 2):ii1–ii54. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Armstrong C: Lung cancer screening recommendations from the ACCP. Am Fam Physician. 98:688–689. 2018.PubMed/NCBI | |
|
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:497–530. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Oncology Society of Chinese Medical Association; Chinese Medical Association Publishing House. Chinese medical association guideline for clinical diagnosis and treatment of lung cancer (2022 edition). Zhonghua Zhong Liu Za Zhi. 44:457–490. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Suzuki K, Watanabe SI, Wakabayashi M, Saji H, Aokage K, Moriya Y, Yoshino I, Tsuboi M, Nakamura S, Nakamura K, et al: A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg. 163:289–301.e2. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Borghesi A, Michelini S, Nocivelli G, Silva M, Scrimieri A, Pezzotti S, Maroldi R and Farina D: Solid indeterminate pulmonary nodules less than or equal to 250 mm3: Application of the updated fleischner society guidelines in clinical practice. Radiol Res Pract. 2019(7218258)2019.PubMed/NCBI View Article : Google Scholar | |
|
Borghesi A, Michelini S, Scrimieri A, Golemi S and Maroldi R: Solid indeterminate pulmonary nodules of less than 300 mm3: Application of different volume doubling time cut-offs in clinical practice. Diagnostics (Basel). 9(62)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhan Y, Peng X, Shan F, Feng M, Shi Y, Liu L and Zhang Z: Attenuation and morphologic characteristics distinguishing a ground-glass nodule measuring 5-10 mm in diameter as invasive lung adenocarcinoma on thin-slice CT. AJR Am J Roentgenol. 213:W162–W170. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hui H, Yin HT, Wang T and Chen G: Computed tomography-guided core needle biopsy for sub-centimeter pulmonary nodules. Kardiochir Torakochirurgia Pol. 19:65–69. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Chen W, Li M, Mao D, Ge X, Wang J, Tan M, Ma W, Huang X, Lu J, Li C, et al: Radiomics signature on CECT as a predictive factor for invasiveness of lung adenocarcinoma manifesting as subcentimeter ground glass nodules. Sci Rep. 11(3633)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kutob L and Schneider F: Lung cancer staging. Surg Pathol Clin. 13:57–71. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Pasic A, Postmus PE and Sutedja TG: What is early lung cancer? A review of the literature. Lung Cancer. 45:267–77. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Mi J, Wang S, Li X and Jiang G: Clinical characteristics and prognosis of sub-centimeter lung adenocarcinoma. Zhongguo Fei Ai Za Zhi. 22:500–506. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Shen C, Wu Q, Xia Q, Cao C, Wang F, Li Z and Fan L: Establishment of a malignancy and benignancy prediction model of sub-centimeter pulmonary ground-glass nodules based on the inflammation-cancer transformation theory. Front Med (Lausanne). 9(1007589)2022.PubMed/NCBI View Article : Google Scholar | |
|
Ginsberg RJ and Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung cancer study group. Ann Thorac Surg. 60:615–623. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Jiang W, Pang X, Xi J, Chen X, Wang Q, Qian C and Fan H: Clinical outcome of subcentimeter non-small cell lung cancer after surgical resection: Single institution experience of 105 patients. J Surg Oncol. 110:233–238. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bai W, Zhang J, Wang Y, Zhou M, Liu L, Wang G, Zhao K, Gao X and Li S: Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: A population-based study. Expert Rev Anticancer Ther. 22:215–228. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, et al: Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 399:1607–1617. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, et al: Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. N Engl J Med. 388:489–498. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Miyajima M, Maki R, Arai W, Tsuruta K, Shindo Y, Nakamura Y and Watanabe A: Robot-assisted vs video-assisted thoracoscopic surgery in lung cancer. J Thorac Dis. 14:1890–1899. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Qi F, Xiang M, Deng Y, Huang W and Sun Y: Application of Da Vinci Robot and thoracoscopy in radical lung cancer surgery. J Healthc Eng. 2022(2011062)2022.PubMed/NCBI View Article : Google Scholar | |
|
Shimomura M, Ishihara S and Inoue M: Robot-assisted segmentectomy for lung cancer. Kyobu Geka. 76:79–83. 2023.PubMed/NCBI(In Japanese). | |
|
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 7:78985–78993. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Harrison PT, Vyse S and Huang PH: Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 61:167–179. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Rosell R, Cardona AF, Arrieta O, Aguilar A, Ito M, Pedraz C, Codony-Servat J and Santarpia M: Coregulation of pathways in lung cancer patients with EGFR mutation: Therapeutic opportunities. Br J Cancer. 125:1602–1611. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, Chen HW, Chang GC, Chang YL, Wu CT, et al: Proteogenomics of non-smoking lung cancer in east asia delineates molecular signatures of pathogenesis and progression. Cell. 182:226–244.e17. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chang YS, Tu SJ, Chen YC, Liu TY, Lee YT, Yen JC, Fang HY and Chang JG: Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Respir Res. 22(3)2021.PubMed/NCBI View Article : Google Scholar | |
|
Tsubata Y, Tanino R and Isobe T: Current therapeutic strategies and prospects for EGFR mutation-positive lung cancer based on the mechanisms underlying drug resistance. Cells. 10(3192)2021.PubMed/NCBI View Article : Google Scholar | |
|
Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, et al: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6. Lancet Oncol. 16:830–838. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, et al: Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 38:124–136. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Gerber DE, Mayer M, Gagan J and von Itzstein MS: Systemic and intracranial efficacy of osimertinib in EGFR L747P-mutant NSCLC: Case report. JTO Clin Res Rep. 3(100291)2022.PubMed/NCBI View Article : Google Scholar | |
|
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, et al: Updated analysis of NEJ009: Gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR. J Clin Oncol. 40:3587–3592. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Shirley M and Keam SJ: Aumolertinib: A review in non-small cell lung cancer. Drugs. 82:577–584. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Wang J and Wu L: An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Expert Opin Pharmacother. 23:647–652. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, et al: Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 383:1711–1723. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, et al: Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer. Oncologist. 24:e1070–e1081. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Bernabé-Caro R, Garrido P, García-Campelo R, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, et al: Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: Results from the Spanish early access program. Oncotarget. 13:812–827. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, et al: Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. ESMO Open. 7(100527)2022.PubMed/NCBI View Article : Google Scholar | |
|
Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, et al: Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial. JAMA Oncol. 7:1617–1625. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, et al: Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 9(e002891)2021.PubMed/NCBI View Article : Google Scholar | |
|
Riudavets M, Cascetta P and Planchard D: Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. Lung Cancer. 169:102–114. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Tan AC and Tan DSW: Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 40:611–625. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Kelly RJ: Dabrafenib and trametinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 18:1063–1068. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X and Zhou C: Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med. 8:2858–2866. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Parekh PR, Botting GM, Thurber DB, Boruszczak M, Murphy W and Bertenshaw GP: Predictive biomarkers for response to trametinib in non-small cell lung cancer. Tumour Biol. 44:249–267. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, Quoix E, Souquet PJ, Barlesi F, Baik C, et al: Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: Updated 5-year survival rates and genomic analysis. J Thorac Oncol. 17:103–115. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M and Büttner R: Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol. 84:184–198. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhu X, Lu Y and Lu S: Landscape of savolitinib development for the treatment of non-small cell lung cancer with MET alteration-A narrative review. Cancers (Basel). 14(6122)2022.PubMed/NCBI View Article : Google Scholar | |
|
Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, Liang Z, Cheng Y, Jiang L, Yang N, et al: Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: A multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 9:1154–1164. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, et al: Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001. Ann Oncol. 30:1121–1126. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Salgia R, Pharaon R, Mambetsariev I, Nam A and Sattler M: The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2(100186)2021.PubMed/NCBI View Article : Google Scholar | |
|
Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB and Villaruz LC: Overcoming KRAS-mutant lung cancer. Am Soc Clin Oncol Educ Book. 42:1–11. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Tsubokawa N, Tsutani Y, Miyata Y, Handa Y, Misumi K, Hanaki H, Hida E and Okada M: Segmentectomy versus lobectomy for radiologically pure solid clinical T1a-bN0M0 lung cancer. World J Surg. 42:2493–2501. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Skoulidis F and Heymach JV: Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 19:495–509. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Drusbosky LM, Rodriguez E, Dawar R and Ikpeazu CV: Therapeutic strategies in RET gene rearranged non-small cell lung cancer. J Hematol Oncol. 14(50)2021.PubMed/NCBI View Article : Google Scholar | |
|
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, et al: Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 22:959–969. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Jiao XD, Qin BD, You P, Cai J and Zang YS: The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer. 123:70–55. 2018.PubMed/NCBI View Article : Google Scholar | |
|
La Fleur L, Falk-Sörqvist E, Smeds P, Berglund A, Sundström M, Mattsson JS, Brandén E, Koyi H, Isaksson J, Brunnström H, et al: Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer. 130:50–58. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xu F, Lin H, He P, He L, Chen J, Lin L and Chen Y: A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma. Oncoimmunology. 9(1731943)2020.PubMed/NCBI View Article : Google Scholar | |
|
Abbosh C, Venkatesan S, Janes SM, Fitzgerald RC and Swanton C: Evolutionary dynamics in pre-invasive neoplasia. Curr Opin Syst Biol. 2:1–8. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, et al: Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. 42:296–303. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Chen H, Carrot-Zhang J, Zhao Y, Hu H, Freeman SS, Yu S, Ha G, Taylor AM, Berger AC, Westlake L, et al: Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun. 10(5472)2019.PubMed/NCBI View Article : Google Scholar | |
|
Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, et al: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 10(2978)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang C, Zhang J, Xu FP, Wang YG, Xie Z, Su J, Dong S, Nie Q, Shao Y, Zhou Q, et al: Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol. 14:1912–1923. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yu F, Peng M, Bai J, Zhu X, Zhang B, Tang J, Liu W, Chen C, Wang X, Chen M, et al: Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules. Int J Cancer. 151:2020–2030. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Li Y, Li X, Li H, Zhao Y, Liu Z, Sun K, Zhu X, Qi Q, An B, Shen D, et al: Genomic characterisation of pulmonary subsolid nodules: Mutational landscape and radiological features. Eur Respir J. 55(1901409)2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen K, Bai J, Reuben A, Zhao H, Kang G, Zhang C, Qi Q, Xu Y, Hubert S, Chang L, et al: Multiomics analysis reveals distinct immunogenomic features of lung cancer with ground-glass opacity. Am J Respir Crit Care Med. 204:1180–1192. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Saito M, Suzuki H, Kono K, Takenoshita S and Kohno T: Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today. 48:1–8. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul S, Arcila ME, et al: The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res. 26:5701–5708. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yu Y and Tian X: Analysis of genes associated with prognosis of lung adenocarcinoma based on GEO and TCGA databases. Medicine (Baltimore). 99(e20183)2020.PubMed/NCBI View Article : Google Scholar | |
|
Li S, Choi YL, Gong Z, Liu X, Lira M, Kan Z, Oh E, Wang J, Ting JC, Ye X, et al: Comprehensive characterization of oncogenic drivers in asian lung adenocarcinoma. J Thorac Oncol. 11:2129–2140. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Shi H, Seegobin K, Heng F, Zhou K, Chen R, Qin H, Manochakian R, Zhao Y and Lou Y: Genomic landscape of lung adenocarcinomas in different races. Front Oncol. 12(946625)2022.PubMed/NCBI View Article : Google Scholar | |
|
Wu SG, Liu YN, Yu CJ, Yang JC and Shih JY: Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes Cancer. 57:513–521. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, Marchionni L, Agrawal N, Ravi R, Jones S, et al: Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun. 6(8258)2015.PubMed/NCBI View Article : Google Scholar | |
|
Sivakumar S, Lucas FAS, Mcdowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, et al: Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res. 77:6119–6130. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, et al: Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun. 12(2722)2021.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka K, Hida T, Oya Y, Yoshida T, Shimizu J, Mizuno T, Kuroda H, Sakakura N, Yoshimura K, Horio Y, et al: Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Cancer. 123:1731–1740. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Han X, Ren P and Ma S: Bioinformatics analysis reveals three key genes and four survival genes associated with youth-onset NSCLC. Open Med (Wars). 17:1123–1133. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et al: Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 48:607–616. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Van Dijk EL, Jaszczyszyn Y, Naquin D and Thermes C: The third revolution in sequencing technology. Trends Genet. 34:666–681. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Hieggelke L and Schultheis AM: Application of FISH in the diagnosis of lung cancer. Pathologe. 41:582–588. 2020.PubMed/NCBI View Article : Google Scholar : (In German). | |
|
Su C, Liu WX, Wu LS, Dong TJ and Liu JF: Screening of hub gene targets for lung cancer via microarray data. Comb Chem High Throughput Screen. 24:269–285. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA and Curigliano G: Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol. 133:171–182. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xu X, Li N, Zhao R, Zhu L, Shao J and Zhang J: Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ. J Cancer Res Clin Oncol. 143:2447–243. 2017.PubMed/NCBI View Article : Google Scholar | |
|
De Scordilli M, Michelotti A, Bertoli E, De Carlo E, Del Conte A and Bearz A: Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: Current evidence and ongoing trials. Int J Mol Sci. 23(7222)2022.PubMed/NCBI View Article : Google Scholar | |
|
Sepesi B, Zhou N, William WN Jr, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, et al: Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 164:1327–1337. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Nagano T, Tachihara M and Nishimura Y: Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer. Curr Cancer Drug Targets. 19:595–630. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda N, Nakayama H and Okada M: The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 164:1306–13015.e4. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, et al: Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 158:406–615. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yi QQ, Yang R, Shi JF, Zeng NY, Liang DY, Sha S and Chang Q: Effect of preservation time of formalin-fixed paraffin-embedded tissues on extractable DNA and RNA quantity. J Int Med Res. 48(300060520931259)2020.PubMed/NCBI View Article : Google Scholar | |
|
Kim YH, Nishimura Y and Funada Y: How should we manage non-small-cell lung cancer ‘not-otherwise-specified’? Med Oncol. 38(82)2021.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Liu X, Li J and Ren F: Identification and integrated analysis of key biomarkers for diagnosis and prognosis of non-small cell lung cancer. Med Sci Monit. 25:9280–9289. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Shi Y, Zhu S, Yang J, Shao M, Ding W, Jiang W, Sun X and Yao N: Investigation of potential mechanisms associated with non-small cell lung cancer. J Comput Biol. 27:1433–1442. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang L, Qu J, Liang Y, Zhao D, Rehman FU, Qin K and Zhang X: Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis. Thorac Cancer. 11:851–866. 2020.PubMed/NCBI View Article : Google Scholar |
